Lp(a)水平降低94%!礼来长效siRNA疗法II期研究结果出炉

医药魔方
31 Mar

3月30日,礼来宣布其小干扰RNA(siRNA)疗法lepodisiran的II期ALPACA研究取得积极结果。该疗法旨在降低脂蛋白(a)(Lp(a))的生成,Lp(a)是心血管疾病的遗传风险因素。在ALPACA研究中,lepodisiran在最高剂量(400mg)下,使Lp(a)水平在治疗后60至180天期间平均降低93.9%,达到主要终点,其中一些患者的降低时间持续近1.5年。接受...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10